Novel combinations and targeted pathway inhibitors may improve adherence and blood pressure control in patients with ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with uncontrolled hypertension in ...

Aldosterone synthase (CYP11B2) is the key enzyme responsible for the final steps in aldosterone production, a steroid hormone that plays a critical role in the regulation of electrolyte balance and ...

Kyushu University researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas (APAs)-adrenal gland tumors that drive high blood pressure. Using cutting-edge analysis ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...

Among selected people with uncontrolled hypertension, blood pressure (BP) could be successfully reduced with a highly selective aldosterone synthase inhibitor, a phase II dose-finding trial found. In ...

Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include ...

Aldosterone is a hormone that causes salt retention, which raises blood pressure. Some people have abnormally high aldosterone levels, but it's difficult to accurately assess aldosterone levels ...